Lataa...
Risk factors in multiple myeloma: is it time for a revision?
Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit fr...
Tallennettuna:
| Julkaisussa: | Blood |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7808011/ https://ncbi.nlm.nih.gov/pubmed/33024991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004309 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|